Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases
There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients.- Targeted therapy in NSCLC is a highly competitive and differentiated space covering ten different actionable biomarkers.
- Treatment development for EGFR mutations shifts from label expansion and CNS activity to overcoming resistance mechanisms.
- The relatively quiet ALK and ROS1 segments are to be reshaped by Nuvalent’s TKIs with better efficacy and safety.
- Small molecule + anti-PD-1 combo therapy will unlock new first-line opportunity in the KRAS G12C segment.
Scope
- This report includes ten actionable biomarkers in NSCLC that are addressed by targeted therapy agents across multiple lines of therapy. Current and future state of these market segments is included in the scope of the report.
Table of Contents
1. Preface1.1. Contents
1.2. Abbreviations
2. Executive Summary
3. Key Market Drivers and Challenges
3.1. Targeted therapy in NSCLC is a highly competitive and differentiated space covering 10 different actionable biomarkers
4. EGFR Segment
4.1. Development focus shift away from label expansion and CNS activity to overcoming resistance mechanism in the busy EGFR segment
5. ALK and ROS1 Segments
5.1. The relatively quiet ALK and ROS1 segments are to be reshaped by Nuvalent’s TKIs with better efficacy and safety
6. KRAS G12C Segment
6.1. Small molecule + PD-1i combo therapy will unlock new 1L opportunity in the KRAS G12C segment
7. HER2, NRG1, BRAF and MET ex14 Segments
7.1. HER2 and NRG1+ segments are evolving NSCLC segments while BRAF and METex14 skipping remain static
8. Appendix
8.1. About the Authors
9. Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson & Johnson, Inc
- AstraZeneca
- Pfizer
- Boehringer Ingelheim
- Lilly
- Roche
- Cullinan Therapeutics Inc
- AbbVie AG
- Arrivent Biopharma Inc
- Hutchmed China Ltd
- Daiichi Sankyo Inc
- Xcovery Holdings Inc
- Nuvalent Inc
- Nuvation Bio Inc
- Bristol-Myers Squibb AB
- Novartis AG
- Amgen AB
- MSD B.V.
- Jiangsu Hengrui Medicine Co Ltd
- Merus Pharma Inc
- Apollomics Inc
